Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: study protocol for a multicenter randomized phase II trial (the OCUU-CRPC study)

BACKGROUND: Enzalutamide is an oral androgen receptor targeted agent that has been shown to improve survival in PREVAIL trials and has been approved for patients with chemo-naïve metastatic castration-resistant prostate cancer (CRPC). Meanwhile, flutamide is a non-steroidal oral anti-androgen that w...

Descripción completa

Detalles Bibliográficos
Autores principales: Iguchi, Taro, Tamada, Satoshi, Kato, Minoru, Yasuda, Sayaka, Yamasaki, Takeshi, Nakatani, Tatsuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6458677/
https://www.ncbi.nlm.nih.gov/pubmed/30971225
http://dx.doi.org/10.1186/s12885-019-5526-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6458677/
https://www.ncbi.nlm.nih.gov/pubmed/30971225
http://dx.doi.org/10.1186/s12885-019-5526-3

Ejemplares similares